“We are at a turning point in the history of cancer,” said Scott Gottlieb, MD, commissioner of the U.S. Food and Drug Administration (FDA), addressing the crowded room of ASCO attendees during the Opening Session on June 2.
With recent approvals of pembrolizumab and nivolumab for the treatment of refractory deficient mismatch repair (dMMR) metastatic colorectal cancer (CRC), immunotherapy has made its way into the field of gastrointestinal oncology.
The combination of ibrutinib and rituximab significantly improved progression-free survival (PFS) and response rates compared to placebo plus rituximab in patients with Waldenström’s macroglobulinemia (WM).
Rearranged during transfection (RET) is an oncogene activated by RET fusions or RET mutations. RET fusions are associated with 2% of non–small cell lung cancers (NSCLCs), 10%-20% of papillary and other thyroid cancers, and smaller proportions of other cancers.
The use of adjuvant chemotherapy to reduce the recurrence of breast cancer has been linked to significant improvements in mortality and morbidity, including disease-free survival (DFS) and overall survival (OS), in women with early-stage disease.
Rejin Kebudi, MD, a professor of pediatrics and a pediatric hematologist-oncologist with Istanbul University, Turkey, is the 2018 recipient of the International Women Who Conquer Cancer Mentorship Award.
Cancer care has a considerable economic impact worldwide. In 2015, the Agency for Healthcare Research and Quality (AHRQ) estimated that the direct medical costs (total of all health care costs) for cancer in the United States were $80.2 billion.